RSV Prevention Guidelines in UAE

Author: Sanofi

Editorial Team

Long acting Monoclonal Antibody is now mandatory for all infants in UAE

Long acting Monoclonal Antibody is now mandatory for all infants in UAE¹

UAE National Immunization Program will include RSV long-acting monoclonal Anti body
SINGLE dose RSV mAb at birth to all infants born from September 1^st to March 1^st

Inclusion in Immunization Program:

One dose of L-mAbs for RSV prevention is indicated for infants born during the RSV season (Sept 1 - March 1) in the following cases:
- If the mother did not receive the RSV vaccine
- If the infant was born within 14 days of maternal RSV vaccination
- If the maternal RSV vaccination status during pregnancy is unknown

High-Risk Children: Only Nirsevimab will be administered in the second RSV season to high-risk children aged 8 to 19 months.

A single dose of the Long-acting RSV monoclonal antibodies is administered to newborns at birth who are born between September 1 of one calendar year and March 1 of subsequent year (RSV season), unless the mother received the RSV vaccine during that pregnancy
Nirsevimab is recommended for some children <19 months who are at increased risk for severe RSV disease and entering their RSV season (1st September to 1st March).
- Children with chronic lung disease of prematurity who required medical support (any time during the 6-month period before the start of the RSV season)
- Children with severe immunocompromise.

References

MAT-AE-2600673-V1-July 2026